Seegene multiplex PCR test, QIAGEN launches new panel, at-home HIV tests. By Diagnostics World Staff July 28, 2026 | Myriad Genetics announces the full commercial launch of FirstGene Multiple Prenatal Screen; Amprion reaches an agreement with Decathlon Capital Partners for a significant growth-funding investment; and more. Myriad Genetics announced the full commercial launch of FirstGene Multiple Prenatal Screen, the only lab test that runs four prenatal genetic screens simultaneously from a single blood draw as early as eight weeks gestation. The FirstGene screen delivers fetal chromosome screening, fetal single-gene screening, patient carrier screening, and fetal RhD screening in one integrated report. The screen has greater than 98% analytical sensitivity and greater than 99% analytical specificity. Press release. Riccio College of Engineering at the University of Massachusetts Amherst received a two-year, $1.3 million award from the National Institutes of Health to advance proof-of-concept work toward commercialization for at-home HIV tests sensitive enough for early diagnosis comparable to - or exceeding - lab standards. This new grant for the phase 2 trial supports the development of their prototype to make it ready for commercialization. This includes refining the prototype design and clinically validating it for self-testing use with 300 patients at Prisma Health in South Carolina. Press release. QIAGEN launched the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel. The panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour. It complements the recently launched QIAstat-Dx BCID GPF Plus AMR Panel in Europe, extending QIAGEN's bloodstream infection testing coverage across gram-positive bacteria, gram-negative bacteria, fungi and key AMR markers. Together, the two panels detect 33 pathogen targets and 28 AMR markers, enabling rapid identification of the most clinically relevant bloodstream pathogens and resistance mechanisms to support earlier pathogen identification and clinical decision-making. Press release. NeoGenomics announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the FDA for patients with prostate adenocarcinoma. The test identifies PTEN protein loss, also known as PTEN deficiency, in patients who may be eligible for AstraZeneca's recently approved targeted therapy TRUQAP (capivasertib). The test is available as a standalone order or as part of NEO PanTracer Pro for prostate cancer, a comprehensive molecular workup that combines CGP and cancer-type-directed IHC testing in a single order built to evolve with new treatment options. Press release. C2N Diagnostics announced that beginning October 1, 2026, eligible Anthem Blue Cross and Blue Shield members will be the first in the United States to receive insurance coverage under a medical policy for the PrecivityAD2 blood test. This policy expands patient access to an innovative blood-based diagnostic test that helps health care professionals evaluate adults experiencing cognitive decline or other signs and symptoms associated with Alzheimer's disease. By providing coverage for eligible patients, the policy helps reduce financial barriers to testing and expands access to innovative diagnostic technologies when deemed medically necessary by a health care professional. Press release. Quest Diagnostics integrated its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR, an electronic health record from Flatiron Health, via a pilot program with American Oncology Network and other community oncology providers. Once completed, the integration will enable 4,700 clinicians across the Flatiron network of 1,600 community-based cancer care locations in the United States to quickly access the Quest services. Press release. Seegene's U.S. subsidiary, Seegene USA, received an Emergency Use Authorization EUA from the FDA for the Allplex HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR assay designed to simultaneously detect multiple viral pathogens associated with clinically overlapping lesion presentations. Seegene's assay is designed to enable the concurrent detection of herpes simplex virus type 1 and type 2 (HSV-1, HSV-2), varicella-zoster virus (VZV), and monkeypox virus (MPXV) in a single test. The Allplex HSV-1&2/VZV/MPXV Assay is the first multiplex PCR test designed to simultaneously and differentially detect viral pathogens of ulcerative skin lesions in the U.S. market. Press release. Seegene also announced the launch of the Global Million Clinical Study (GMCS), aiming to evaluate the clinical utility and potential impact of comprehensive syndromic PCR testing approaches using real-world data. This project is scheduled to begin in South Korea and at healthcare institutions across the world to accumulate large-scale global testing data and assess the clinical value of disease-specific testing approaches for major infectious diseases. The goal is to build the scientific basis for new global testing standards and support a more comprehensive and accurate diagnostic environment, in which everyone, regardless of country or region, can access the best testing currently available. Press release.

Qiagen opens first Experience Lab in Manila. July 11, 2026 NETHERLANDS-BASED life sciences company Qiagen has opened its first Experience Lab in the Philippines, providing researchers, students and industry users with access to molecular testing technologies for demonstrations, training and technical support. The facility, inaugurated on July 7 in partnership with Hamburg Trading Corp., serves as Qiagen's first permanent demonstration laboratory in the country. It allows users to evaluate the company's molecular testing platforms without having to bring equipment into their own institutions. The laboratory features several automated systems, including the QIAsprint Connect, QIAcube Connect and QIAcuity Digital PCR platform. The company said the facility is intended to support applications in academic research, pharmaceutical development, veterinary diagnostics, agriculture and industrial testing. Qiagen said the laboratory will host seminars, technical workshops and hands-on training programs aimed at strengthening local expertise in molecular biology and laboratory workflows. "Beyond serving as a supplier, we are partnering with Hamburg Trading Corp. to transform this facility into a learning hub that supports the next generation of Filipino scientists through hands-on training and technical expertise," said Eric Goh, head of commercial operations for Southeast Asia at Qiagen. The company said the facility also aims to simplify product evaluation by allowing researchers and institutions to test equipment on site instead of arranging temporary installations or equipment imports. Hamburg Trading Corp., Qiagen's local distribution partner, will also use the laboratory as a center for customer support, technical assistance and product training. Qiagen said it sees the Philippines as an important market for applied testing in Southeast Asia, particularly in veterinary diagnostics, plant science and industrial applications, while continuing to support academic institutions and pharmaceutical research. The Manila laboratory expands Qiagen's regional network of demonstration and training facilities. Company officials said it is will strengthen technical support and access to molecular technologies forresearchers and laboratories across the country.

QIAGEN to open an Experience Lab in the Philippines, announces strategic partnership with Hamburg Trading Corporation. Published on July 7, 2026 * Partnership with Hamburg Trading Corp to advance applied testing and life science research * Serving as a learning hub to empower the next generation of Filipino scientists through hands-on access to molecular workflows * Facility designed to remove logistical barriers for researchers, enabling on-site evaluation without the need for internal equipment clearances Manila, the Philippines, July 7, 2026 - QIAGEN, a global provider of Sample to Insight solutions, has officially commenced a new distribution partnership with Hamburg Trading Corporation (Hamburg) for its life sciences business in the Philippines. This collaboration is anchored by the opening of the QIAGEN Experience Lab in the Philippines, a dedicated space designed to bring advanced molecular solutions directly to the local scientific community. As a cornerstone of this partnership, QIAGEN and Hamburg have unveiled a dedicated QIAGEN demo lab in the Philippines. This new facility represents a significant milestone in QIAGEN's regional strategy, establishing a permanent physical presence to support the local scientific community. The partnership features QIAGEN's latest advancements in laboratory automation, including QIAsprint Connect, QIAcube Connect and QIAcuity Digital PCR system. These solutions are available for demonstration within the lab, highlighting QIAGEN's "Sample to Insight" capabilities. The Philippines represents a critical mass applied testing market. The partnership with Hamburg enables QIAGEN to tap into specialized segments, including veterinary, plant testing and industrial applications, while maintaining a robust foothold in academic and pharmaceutical R&D. "Beyond serving as a supplier, we are partnering with Hamburg Trading Corp to transform this facility into a vibrant learning hub that empowers the next generation of Filipino scientists through hands-on seminars and real-world expertise," said Eric Goh, Head of Commercial Operations, Southeast Asia at QIAGEN. "This milestone marks a crucial step in our long-term commitment to the Philippines and the broader Southeast Asian market." The new demo lab is designed to be a platform for real customer engagement, allowing stakeholders from applied testing and life sciences research to experience QIAGEN's expansive portfolio without the need for internal clearances for instrument demos. The Filipino scientific community stands to benefit from direct, hands-on access to the full QIAGEN portfolio, enabling researchers to experience advanced workflows in person. By providing a dedicated space for on-site demonstrations and technical workshops, the lab removes the logistical burden, resulting in a more seamless evaluation process. Furthermore, the facility serves as a vital hub for local expertise, fostering capability building and providing a physical center for internal training and specialized support across the nation. This local, physical presence increases brand credibility in a market that relies on local partners for evaluation and support. As a global leader in Sample to Insight solutions, QIAGEN serves the molecular diagnostics and life sciences sectors across Southeast Asian countries. The company remains dedicated to supporting clinical healthcare, academic research, pharmaceutical R&D and industrial applications through its comprehensive portfolio of consumables and automated solutions. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Its Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the life sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com. Contact QIAGEN: Heeyoung Lee Associate Manager, Marcom, PR&Media Relations, APEC Tel: +82 10 9338 9650 Email: [email protected]